Arcus Biosciences ROE 2017-2022 | RCUS

Current and historical return on equity (ROE) values for Arcus Biosciences (RCUS) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Arcus Biosciences ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2022-12-31 $-0.27B $0.66B -36.83%
2022-09-30 $0.08B $0.70B 10.37%
2022-06-30 $0.07B $0.75B 9.15%
2022-03-31 $0.06B $0.80B 8.32%
2021-12-31 $0.05B $0.84B 7.98%
2021-09-30 $-0.28B $0.54B -48.21%
2021-06-30 $-0.20B $0.61B -34.37%
2021-03-31 $-0.17B $0.67B -31.40%
2020-12-31 $-0.12B $0.50B -30.45%
2020-09-30 $-0.09B $0.54B -27.54%
2020-06-30 $-0.11B $0.43B -49.18%
2020-03-31 $-0.10B $0.14B -55.96%
2019-12-31 $-0.09B $0.16B -44.74%
2019-09-30 $-0.08B $0.18B -38.51%
2019-06-30 $-0.07B $0.20B -30.70%
2019-03-31 $-0.06B $0.22B -22.99%
2018-12-31 $-0.05B $0.24B -19.96%
2018-09-30 $-0.05B $0.25B -22.15%
2018-06-30 $-0.06B $0.26B -37.28%
2018-03-31 $-0.06B $0.27B -56.06%
2017-12-31 $-0.05B $0.15B -137.66%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.194B $0.112B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $140.576B 8.70
GSK (GSK) United Kingdom $75.923B 9.52
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.436B 19.34
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Biohaven (BHVN) United States $0.913B 0.00
Emergent Biosolutions (EBS) United States $0.394B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.106B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.012B 0.00